EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial

Nur Izreena Ismail, Khairul Najmi Muhammad Nawawi, Deborah Chew Chia Hsin, Kok Wei Hao, Nik Ritza Kosai Nik Mahmood, Gary Lee Chong Chearn, Zhiqin Wong, Azmi Mohd Tamil, Hazel Joseph, Raja Affendi Raja Ali

Helicobacter · 2023

DOI: 10.1111/hel.13017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2023. Verfasst von Nur Izreena Ismail und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Limosilactobacillus reuteri, Dyspepsia. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Y.S.P. Industries (M) Sdn. Bhd., Marathon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite multiple therapy regimens, the decline in the Helicobacter pylori eradication rate poses a significant challenge to the medical community. Adding Lactobacillus reuteri probiotic as an adjunct treatment has shown some promising results. This study aims to investigate the efficacy of Lactobacillus reuteri DSM 17648 in H. pylori eradication and its effect in ameliorating gastrointestinal symptoms and adverse treatment effects. Materials and Methods This randomized, double‐blinded, placebo‐controlled trial involved treatment‐naïve H. pylori ‐positive patients. Ninety patients received standard triple therapy for 2 weeks before receiving either a probiotic or placebo for 4 weeks. The posttreatment eradication rate was assessed via a 14 C urea breath test in Week 8. The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire and an interview on treatment adverse effects were conducted during this study.

Results

The eradication rate was higher in the probiotic group than in the placebo group, with a 22.2% difference in the intention‐to‐treat analysis (91.1% vs. 68.9%; p = 0.007) and 24.3% difference in the per‐protocol analysis (93.2% vs. 68.9%; p = 0.007). The probiotic group showed significant pre‐ to post‐treatment reductions in indigestion, constipation, abdominal pain, and total GSRS scores. The probiotic group showed significantly greater reductions in GSRS scores than the placebo group: indigestion (4.34 ± 5.00 vs. 1.78 ± 5.64; p = 0.026), abdominal pain (2.64 ± 2.88 vs. 0.89 ± 3.11; p = 0.007), constipation (2.34 ± 3.91 vs. 0.64 ± 2.92; p = 0.023), and total score (12.41 ± 12.19 vs. 4.24 ± 13.72; p = 0.004). The probiotic group reported significantly fewer adverse headache (0% vs. 15.6%; p = 0.012) and abdominal pain (0% vs. 13.3%; p = 0.026) effects.

Conclusions

There was a significant increase in H. pylori eradication rate and attenuation of symptoms and adverse treatment effects when L. reuteri was given as an adjunct treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriLimosilactobacillus reuteriDyspepsiaGastrointestinal DiseasesProbioticsHumansAnti-Bacterial AgentsDrug Therapy, CombinationAbdominal PainConstipationTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriLactobacillus reuteriGSRSeradicationgastrointestinal symptom rating scaleprobiotics

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • Minimally Invasive, Upper Gastrointestinal and Bariatric Surgery Unit, Department of Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • Pantai Hospital, Kuala Lumpur, Malaysia.
  • Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • Y.S.P. Industries (M) Sdn. Bhd, Kuala Lumpur, Malaysia.

Förderung

  • Y.S.P. Industries (M) Sdn. Bhd.
  • Marathon

Zitieren

APA

Ismail, N. I., Nawawi, K. N. M., Hsin, D. C. C., Hao, K. W., Mahmood, N. R. K. N., Chearn, G. L. C., Wong, Z., Tamil, A. M., Joseph, H., & Raja Ali, R. A. (2023). Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial. Helicobacter. https://doi.org/10.1111/hel.13017

Vancouver

Ismail NI, Nawawi KNM, Hsin DCC, Hao KW, Mahmood NRKN, Chearn GLC, et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial. Helicobacter. 2023. doi:10.1111/hel.13017

BibTeX
@article{Ismail2023,
  author = {Ismail, Nur Izreena and Nawawi, Khairul Najmi Muhammad and Hsin, Deborah Chew Chia and Hao, Kok Wei and Mahmood, Nik Ritza Kosai Nik and Chearn, Gary Lee Chong and Wong, Zhiqin and Tamil, Azmi Mohd and Joseph, Hazel and Raja Ali, Raja Affendi},
  title = {Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double‐blind, placebo‐controlled trial},
  journal = {Helicobacter},
  year = {2023},
  doi = {10.1111/hel.13017}
}
Kostenlos starten →